EDROPHONIUM CHLORIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EDROPHONIUM CHLORIDE (EDROPHONIUM CHLORIDE).
Inhibits acetylcholinesterase, prolonging acetylcholine action at neuromuscular junction and autonomic ganglia.
| Metabolism | Hepatic metabolism via hydrolysis by plasma esterases and hepatic enzymes. |
| Excretion | Primarily renal excretion as unchanged drug (approximately 70-80% within 4 hours); minor biliary/fecal elimination accounts for <10%. |
| Half-life | Terminal elimination half-life is 1.5-2 hours; in anephric patients, half-life may be prolonged up to 6-8 hours, requiring dose adjustment. |
| Protein binding | Approximately 20-30% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | 0.2-0.4 L/kg; distribution is limited to extracellular fluid with minimal tissue binding. |
| Bioavailability | Intramuscular: approximately 80-90% due to some first-pass metabolism; oral bioavailability is low (<10%) and clinically not used for systemic effects. |
| Onset of Action | Intravenous: 30-60 seconds; intramuscular: 2-10 minutes. |
| Duration of Action | Intravenous: 5-10 minutes for reversal of nondepolarizing neuromuscular blockade; higher doses for myasthenia gravis diagnosis produce effects lasting 10-30 minutes. Duration is dose-dependent. |
10 mg IV bolus, may repeat up to total 10 mg. For myasthenia gravis diagnosis: 2 mg IV test dose, then 8 mg IV if no reaction after 45 seconds.
| Dosage form | INJECTABLE |
| Renal impairment | eGFR 10-50 mL/min: reduce dose by 50%. eGFR <10 mL/min: avoid use or reduce dose by 75%. |
| Liver impairment | No specific Child-Pugh based adjustments. Use with caution in severe hepatic impairment due to potential accumulation; consider reduced initial dose. |
| Pediatric use | Infants/children: 0.1-0.2 mg/kg IV, not to exceed 10 mg total. For diagnosis: 0.04 mg/kg test dose, then 0.16 mg/kg if tolerated. |
| Geriatric use | Reduce dose by 50% due to reduced renal function and increased sensitivity. Monitor for bradycardia and hypotension. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for EDROPHONIUM CHLORIDE (EDROPHONIUM CHLORIDE).
| Breastfeeding | Not known whether edrophonium is excreted into human milk. No M/P ratio available. Use with caution in nursing mothers due to potential for cholinergic effects in the infant, including gastrointestinal disturbances or weakness. |
| Teratogenic Risk | Pregnancy Category C. No adequate human studies; animal studies not reported. Fetal risk cannot be ruled out. Use only if potential benefit justifies risk. Edrophonium is a quaternary ammonium compound; placental transfer is limited due to ionization. First trimester: theoretical risk of teratogenicity due to cholinergic effects; avoid if possible. Second and third trimesters: may cause transient neonatal weakness if given near term. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to edrophonium or anticholinesterases; mechanical intestinal or urinary obstruction; post-vagotomy patients with GI hypermotility.
| Precautions | Bradycardia, asystole, respiratory depression, and cholinergic crisis; monitor cardiac and respiratory function; have atropine available; use with caution in asthma, arrhythmias, and after vagotomy. |
Loading safety data…
| Fetal Monitoring | Maternal: Heart rate, blood pressure, respiratory function, and signs of cholinergic crisis (bradycardia, hypotension, bronchospasm). Fetal: Heart rate monitoring during labor if used for reversal of neuromuscular blockade; assess neonatal tone and respiratory effort after delivery. |
| Fertility Effects | No human data on fertility effects. In animal studies, no adverse effects on fertility reported. Theoretical risk of cholinergic effects on reproductive tissues, but unlikely at clinical doses. |